Nibix Pharmaceuticals to issue 1,375,000 ordinary shares; Muktinath Capital appointed as underwriter.
Nibix Pharmaceuticals Limited has signed an agreement with Muktinath Capital Limited for underwriting 13,75,000 ordinary shares to be issued to the public. The agreement was signed by Nibix’s Managing Director Indra Wania and Muktinath Capital’s Chief Executive Officer Kabindra Dhwaj Joshi.
The signing ceremony was also attended by Nibix Pharmaceuticals’ Chairman Kalidas Paudel, Director Pharmacist Sujan Chandra Sigdel, and Chartered Accountant Anil Paudel.
Established in 2074 B.S., Nibix Pharmaceuticals Limited converted into a public limited company on Poush 2, 2081 B.S. It has obtained production and marketing approval from the Department of Drug Administration and currently produces 56 types of medicines.
The company mainly manufactures medicines used in the treatment of cardiovascular diseases, diabetes, respiratory disorders, liver, and digestive system diseases. Additionally, Nibix Pharmaceuticals is conducting research on new medicines and preparing to expand its production line.
The company plans to issue an IPO of 13,75,000 shares, for which Muktinath Capital Limited has been appointed as the underwriter.
This article was originally published on https://bajarkochirfar.com. Translated with the help of AI and reviewed by our editorial team.
